Your browser doesn't support javascript.
loading
CSF ß-amyloid predicts prognosis in patients with multiple sclerosis.
Pietroboni, Anna M; Caprioli, Michela; Carandini, Tiziana; Scarioni, Marta; Ghezzi, Laura; Arighi, Andrea; Cioffi, Sara; Cinnante, Claudia; Fenoglio, Chiara; Oldoni, Emanuela; De Riz, Milena A; Basilico, Paola; Fumagalli, Giorgio G; Colombi, Annalisa; Giulietti, Giovanni; Serra, Laura; Triulzi, Fabio; Bozzali, Marco; Scarpini, Elio; Galimberti, Daniela.
Afiliación
  • Pietroboni AM; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Caprioli M; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Carandini T; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Scarioni M; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Ghezzi L; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Arighi A; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Cioffi S; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Cinnante C; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Fenoglio C; University of Milan, Dino Ferrari Center, Milan, Italy.
  • Oldoni E; Laboratory for Neuroimmunology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • De Riz MA; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Basilico P; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Fumagalli GG; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy/Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy/University of Milan, Milan, Italy.
  • Colombi A; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Giulietti G; Neuroimaging Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy.
  • Serra L; Neuroimaging Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy.
  • Triulzi F; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Bozzali M; Neuroimaging Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy/ Department of Neuroscience, Brighton and Sussex Medical School, University of Sussex, Brighton, UK.
  • Scarpini E; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
  • Galimberti D; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy/University of Milan, Dino Ferrari Center, Milan, Italy.
Mult Scler ; 25(9): 1223-1231, 2019 08.
Article en En | MEDLINE | ID: mdl-30084711
BACKGROUND: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. OBJECTIVES: To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta1-42 (Aß) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white matter (WM) and grey matter (GM) damage at early disease stages. METHODS: Sixty patients were recruited and followed up for 3-5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aß levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. RESULTS: Lower CSF Aß levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; r = -0.65, p < 0.001). The multiple regression analysis confirmed CSF Aß concentration as a predictor of patients' EDSS increase (r = -0.59, p < 0.0001). Generating a receiver operating characteristic curve, a cut-off value of 813 pg/mL was determined as the threshold able to identify patients with worse prognosis (95% confidence interval (CI): 0.690-0.933, p = 0.0001). No differences in CSF tau and neurofilament light chain (NfL) levels were observed (p > 0.05). CONCLUSION: Low CSF Aß levels may represent a predictive biomarker of disease progression in MS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Péptidos beta-Amiloides / Progresión de la Enfermedad / Sustancia Blanca / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Péptidos beta-Amiloides / Progresión de la Enfermedad / Sustancia Blanca / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido